Advances in the understanding of human soft tissue sarcomas: Molecular biology and therapeutic strategies (Review)

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1275-1279

  Milas, Mira ^a   Yu, Dihua ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene therapy; p53; Sarcoma

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; GENE THERAPY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

EID: 0031856727     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1275     Document Type: Review

References (55)

1. Pollock RE, Kamell LH, Menck HR and Winchester DP: The National cancer data base report on soft tissue sarcoma. Cancer 78: 2247-2257, 1996.
2. Pisters PW, Fein DA and Somlo G: Soft-tissue sarcomas. In: Cancer Management: A Multidisciplinary Approach. Pazdur R, et al (eds). PRR, Huntington, NY, pp491-505, 1996.
3. Yang JC, Rosenberg SA, Glatstein EJ and Antman KH: Sarcomas of soft tissues. In: Cancer: Principles and Practice of Oncology. DeVita VT, et al (eds). J.B. Lippincott Co., Philadelphia, pp1436-1488, 1993.
4. Meterissian SH and Tanabe KK: Bone and soft-tissue sarcoma. In: The M.D. Anderson Surgical Oncology Handbook. Berger DH, et al (eds). Little, Brown and Company, Boston, pp70-84, 1995.
5. Spiro IJ, Rosenberg AE, Springfield D and Suit H: Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience. Cancer Invest 13: 86-95, 1995.
6. Benjamin RS, Pollock RE and Zagars GZ: Soft tissue sarcomas of the extremities: continuing challenges for a multidisciplinary team. Cancer Invest 13: 137-138, 1995.
7. Pollock RE: Limb-sparing therapy for soft-tissue sarcomas. Curr Opin Gen Surg: 224-229, 1994.
8. Yasko AW, Reece GP, Gillis TA and Pollock RE: Limb-salvage strategies to optimize quality of life: the M.D. Anderson Cancer Center experience. CA Cancer J Clin 47: 226-238, 1997.
9. Lienard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
10. Eggermont AM, Schrafford T, Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-764, 1996.
11. Roth JA and Christiano RJ: Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89: 21-39, 1997.
12. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD and Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395-405, 1995.
13. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H and Clayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54: 3662-3667, 1994.
14. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhabg WW, Owen-Schaub LB and Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291, 1994.
15. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL and Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1-6, 1995.
16. Nielsen LL and Maneval DC: p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5: 52-63, 1998.
17. Pollock RE: Molecular determinants of soft tissue sarcoma proliferation. Semin Surg Oncol 10: 315-322, 1994.
18. Perosio PM and Brooks JJ: Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab Invest 60: 245-253, 1989.
19. Roholl PJM, Weima SM, Prinsen I, et al: Expression of growth factors and their receptors on human sarcomas. Immunohistochemical detection of platelet-derived growth factor, epidermal growth factor and their receptors. Cancer J 4: 83-88, 1991.
20. Wang J, Coltrera MD, Gown AM, et al: Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Cancer Res 54: 560-564, 1994.
21. Roholl PJM, Skottner A, Prinsen I, et al: Expression of insulin-like growth factor 1 in sarcomas. Histopatholoay 16: 455-460, 1990.
22. Hu M, Pollock RE and Nicolson GL: Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin. Cancer Res 57: 3577-3584, 1997.
23. Hu M, Pollock RE. Nakamura T and Nicolson GL: Human peritumoral and lung fibroblasts produce paracrine motihty factors for recently established human sarcoma cell strains. Int J Cancer 62: 585-592, 1995.
24. Barrios C, Castresana JS, Ruiz J and Kreicbergs A: Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 51: 13-17, 1994.
25. Smith SH, Weiss SW, Jankowski SA, et al: SAS amplification in soft tissue sarcomas. Cancer Res 52: 3746-3749, 1992.
26. Jankowski SA, Mitchell DS, Smith SH, et al: SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins. Oncogene 9: 1205-1211, 1994.
27. Andreassen A, Oyjord T, Hovig E, et al: p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53: 468-471, 1993.
28. Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Woodruff JM and Cordon-Cardo C: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 145: 345-355, 1994.
29. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
30. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
31. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993.
32. Kinzler KW and Vogelstein B: Cancer therapy meets p53: clinical implications of basic research. N Engl J Med 331: 49-50, 1994.
33. Toguchida J, Yamaguchi T, Ritchie R, Beauchamp RL, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-6199, 1992.
34. Taubert H, Wurl P, Meye A, et al: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histicytoma: identification of seven new mutations for soft tissue sarcomas. Cancer 76: 1187-1196, 1995.
35. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
36. Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF and Cordon-Cardo C: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft tissue sarcomas. J Natl Cancer Inst 86: 549-554, 1994.
37. Taubert H, Meye A and Wuri P: Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56: 4134-4136, 1996.
38. Cance WG, Brennan MF, Dudas ME, et al: Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 323: 1457-1462, 1990.
39. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-86, 1992.
40. Yao J, Pollock RE, Lang A, Tan M, Pisters P, et al: Infrequent mutation of the p16/MTS1 gene and overexpression of cyclindependent kinase in human primary soft-tissue sarcoma. Clin Cancer Res 4: 1065-1070, 1998.
41. Pollock RE, Lang A, Luo J, El-Naggar AK and Yu D: Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 12: 2035-2039, 1996.
42. Knudson AG: Genetics and etiology of human cancer. Adv Hum Genet 8: 1-66, 1977.
43. Pollock RE, Lang A, Ge T, Sun D, Tan M and Yu D: Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res (In press).
44. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW and Diesseroth AB: A temperature-sensitive mutant of human p53. EMBO J 13: 2535-2544, 1994.
45. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
46. Lowe SW, Bodis S, McClatchey A, Remington L, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
47. Wynford-Thomas D, Bond JA, Wyllie FS and Jones CJ: Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinogen 12: 119-123, 1995.
48. Kim NW, Piatyszek MA, Prowse KR, Harley CB, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
49. Milas M, Yu D, Sun D and Pollock RE: Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. Clin Cancer Res 4: 1573-1579, 1998.
50. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
51. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
52. Barinage M: From bench top to bedside. Science 278: 1036-1039, 1997.
53. Oliff A, Gibbs JB and McCormick F: New molecular targets for cancer therapy. Sei Am 275: 144-149, 1996.
54. Gagnebin J, Kovar H, Kajava AV, et al: Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants. Oncogene 16: 685-690, 1998.
55. Milas M, Feig B, Yu D, Oriuchi N, Cromeens D, Ge T, Wong FC, Kim EE and Pollock RE: Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 3: 2197-2203, 1997.